IO360° Summit

Hanif Gabrani-Juma, BEng, MASc, Associate Director – Translational Medicine Strategy Radiology Imaging & AI, Oncology R&D Cancer Biomarker Development, AstraZeneca

4:00PM - 4:20PM

Active Immunotherapy to Achieve Durable Remissions in MRD + AML

Speaker:

Erik Manting, PhD, CEO, Mendus

4:20PM - 4:35PM

Progress on Multiplexed IHC CDx: Advancing Spatial Biology for Clinical Impact

Speaker:

Mark Landers, VP of Precision Medicine, Akoya Biosciences Inc.

4:35PM - 4:55PM

Picking our Horse in the Race for Auto-immunity: The Gamma-Delta T-cell Engager

Speaker:

William Ho, MBA, President & CEO, IN8Bio

4:55PM - 5:10PM

Leveraging the Predictive Power of Liquid Biopsy for IO Treatment Response Monitoring

Speaker:

Kristin Price, Senior Product Director, Guardant Health

5:10PM - 5:25PM

Targeting Metastatic Cancer and Immune Resistance Using Nucleic Acid Therapies

Speaker:

Zdravka Medarova, PhD, CSO & Co-founder, TransCode Therapeutics

Track 3: Cell Therapy - Innovations in Process to Generate Cell Therapies Constitution Ballroom A

Track Chair:

Rosanna Ricafort, MD, VP and Head, Hematology and Cellular Therapy Development, BMS

4:00PM - 4:15PM

Accelerating Cell Therapy: Innovations in Streamlining the Cell Manufacturing Process

Speaker:

Saba Ghassemi, PhD, Research Assistant; Professor of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania

4:15PM - 4:30PM

Non-Viral Vectors Delivering Stably Integrating DNA for In Vivo CAR T Therapy

Speaker:

Maurits Geerlings, MD, MBA, President & CEO, NanoCell Therapeutics, Inc

4:30PM - 4:45PM

In Vivo CD19 and CD22 CAR-T Cell Therapeutics for B Cell Malignancies

Speaker:

Andrew Scharenberg, MD, Co-Founder & CEO, Umoja Biopharma

4:45PM - 5:00PM

Implantable Biofactories for Bedside CAR T Cell Therapy

Speaker:

Yevgeny Brudno, PhD, Associate Professor, University of North Carolina at Chapel Hill and North Carolina State University

5:00PM - 5:15PM

Multiplexed CRISPR Cas9 Editing to Generate Next-Generation Allogeneic CAR-T Cells

Speaker:

Birgit Schultes, PhD, SVP, Head of Cell Therapies, Intellia Therapeutics

Track 4: Cell Therapy - Innovations in Cell Types Employed in Cell Therapies Constitution Ballroom B

Track Chair:

Michael Kalos, PhD, Managing Director, Next Pillar Consulting

4:00PM - 4:15PM

Going with the Flow: Circulating Tumor Reactive Lymphocytes (cTRL) Stream into Cancer Therapy

Speaker:

Ruben Rodriguez, PhD, Head of Research, cTRL Therapeutics

4:15PM - 4:30PM

B Cell Medicines – A New Class of In Vivo Biologics

Speaker:

Joanne Smith-Farrell, PhD, CEO & Director, Be Bio

4:30PM - 4:45PM

Programming T Cells with Synthetic Immunology to Overcome Solid Tumor Barriers

Speaker:

Aaron Cooper, PhD, VP, Early Discovery, ArsenalBio

Showing Events in 1 Track from 05:30pm to 06:10pm

IO360º Cancer Immunotherapy Debate Grand Ballroom

5:30PM - 6:10PM

IO360º Annual Debate: Monotherapy vs Combination Therapies in IO

Participants:

Charles Drake, MD, PhD, VP, Immuno-Oncology, J&J Innovative Medicine

Alexander Eggermont, MD, PhD, CSO / Professor, Clinical & Translational Immunotherapy, Princess Máxima Center for Pediatric Oncology / UMC Utrecht, Utrecht University

Led by:

David Feltquate, MD, PhD, CMO, iTeos Therapeutics

Showing Events in 1 Track from 07:45am to 08:30am

Morning Remarks
Grand Ballroom

7:45AM - 8:15AM

Registration & 1:1 Partnering Meetings

8:15AM - 8:30AM

Day Two Welcome & Tackling the Tough Questions in IO for Autoimmunity Disease

Chair:

William Ho, MBA, President & CEO, IN8Bio

Showing Events in 1 Track from 08:30am to 09:35am

State of the IO Market, Investments and Deals Plenary
Grand Ballroom

Track Chair:

William Ho, MBA, President & CEO, IN8Bio

8:30AM - 8:55AM

Fireside Chat: Strategic Vision and Innovation in IO with Dr Andrew Baum, Pfizer

Fireside Guest:

Andrew Baum, MD, Chief Strategy and Innovation Officer, Pfizer

Moderator:

Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics

8:55AM - 9:15AM

Bispecific Antibodies Targeting PD-1 and VEGF: Impact for the IO Landscape and Market Dynamics

Fireside Participants:

Roy Baynes, MD, PhD, EVP & CMO, Eikon Therapeutics

Asthika Goonewardene, MBA, Managing Director, Senior Biotech Analyst, Truist Securities

9:15AM - 9:35AM

Biotech Markets & IO Outlook

Speaker:

Graig C. Suvannavejh, PhD, Managing Director, Equity Research Biopharmaceuticals & Biotechnology, Mizuho Securities USA

Showing Events in 1 Track from 09:35am to 10:15am

IO360° Morning Networking Break, 1:1 Partnering Meetings & Poster Sessions Begin

9:35AM - 10:15AM

IO360° Morning Networking Break, 1:1 Partnering Meetings & Poster Sessions Begin

9:40AM - 10:10AM

IO360° Poster Sessions Begin

Poster Presenters:

David A. Braun, MD, PhD, Louis Goodman and Alfred Gilman Yale Scholar & Assistant Professor of Medicine, Pathology, and Urology, Yale School of Medicine

Jay Fine, PhD, President, Research & Development, EvolveImmune Therapeutics

Chiquita Hanindya, Scientist, Cell Biology, BlueWhale Bio

Gopal Krishnan, PhD, Manager, Biologics, Promega

Ramji Srinivasan, Co-founder and CEO, Teiko.bio

Kristen Wangerin, PhD, Senior Imaging Technology Leader, Pharmaceutical Diagnostics, GE HealthCare

Alia Zander, PhD, Senior Data Scientist, Machine Learning, Tempus

Jenny Zilberberg, PhD, Head of Research, Imvax, Inc.

Showing Events in 1 Track from 10:15am to 10:50am

IO360º Biotech Showcase

Track Chair:

Leon 'Jun' Tang, PhD, Founder / Scientific Advisor, InScienceWeTrust BioAdvisory / Mianus Capital

10:15AM - 10:50AM

IO360° Biotech Showcase

Speakers:

Tony Arulanandam, PhD, CEO and Founder, Synaptimmune Therapeutics

Victor Goldmacher, Chief Scientific Officer, ImmuVia, Inc.

Vikram Kansra, PhD, Founder & CEO, Vicero Bio

Kuldeep Neote, PhD, CEO, Diadem Biotherapeutics

Pan Pan, PhD, MBA, SVP, Head of Business Development, OncoC4

Participating Companies:

Showing Events in 1 Track from 10:50am to 10:55am

5 Minute Health Break

10:50AM - 10:55AM

5 Minute Health Break

Showing Events in 1 Track from 10:55am to 12:25pm

State of the IO Market, Investments and Deals Plenary (continued)
Grand Ballroom

10:55AM - 11:40AM

Business Development Strategies in IO: M&A, Partnerships, and Biotech Investments

Moderator:

Andrew Baum, MD, Chief Strategy and Innovation Officer, Pfizer

Panelists:

Rick Aldridge, MBChB, Managing Director, Healthcare, Lazard

Rakhshita Dhar, Senior Director, Venture Investments, Health, Leaps by Bayer

Emmett Schmidt, MD, PhD, VP, Clinical Oncology and Lead, External Collaborations, Merck

Gayatri Varma, PhD, Executive Director and Head of Transactions, Oncology R&D, AstraZeneca

Evan Zisholtz, JD, VP, Global Business Development, Immunai

11:40AM - 12:25PM

Navigating Immuno-Oncology Investments in 2025: Fundraising in Capital Markets

Moderator:

Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics

Panelists:

Kalli Dircks, Managing Director, Global Capital Markets, Morgan Stanley

Carl Gordon, PhD, CFA, Managing Partner, OrbiMed Advisors LLC

Rajiv Kaul, Portfolio Manager, Equity Division, Fidelity Investments

Showing Events in 1 Track from 12:25pm to 01:25pm

Lunch

12:25PM - 1:25PM

Lunch & 1:1 Partnering Meetings

Showing Events in 2 Tracks from 01:30pm to 03:20pm

Track 1: Breakthroughs in Translational Science, Imaging and Biomarkers Plenary
Grand Ballroom

Track Chair:

Rachel Salazar, DHSc, SVP, R&D Strategy & Operations, Bicara Therapeutics

1:30PM - 1:55PM

Advancing CAR T Therapies: A New BCMA/CD19 Approach for Treating Multiple Myeloma

Speaker:

Nina Shah, MD, Global Head of Multiple Myeloma Clinical Development and Strategy, Hematology R&D, AstraZeneca

1:55PM - 2:15PM

Advancing Our Understanding of ctDNA Dynamics to Guide Drug Development

Speaker:

Dejan Knezevic, PhD, Senior Director, Pharma Partnerships, Natera

2:15PM - 3:00PM

Panel: AI's Role in Advancing Immuno-Oncology R&D Strategies

Moderator:

Vipul Baxi, MBA, Executive Director, Computational Imaging and Digital Biomarkers, Amgen

Panelists:

Sharon Benzeno, PhD, MBA, Chief Commercial Officer, Immune Medicine, Adaptive Biotechnologies

Olga Kubassova, PhD, Founder and President, Image Analysis Group

B. Dusty Majumdar, PhD, CEO, PredxBio

3:00PM - 3:20PM

Harnessing Spatial Biology for Enhanced Cancer Immunotherapy Treatment

Speaker:

B. Dusty Majumdar, PhD, CEO, PredxBio

Track 2: IO Cell Therapy
Back Bay Ballroom AB

Track Chairs:

Michael Kalos, PhD, Managing Director, Next Pillar Consulting

Rosanna Ricafort, MD, VP and Head, Hematology and Cellular Therapy Development, BMS

1:30PM - 1:55PM

Fireside Chat: Navigating the Evolving Landscape of Cell Therapy - Strategic Shifts and Future Directions

Fireside Guests:

Arjun Goyal, MD, MPhil, MBA, Former Co-founder & Managing Director, Vida Ventures

Sarah Warren, PhD, Senior Director, Corporate Development Lead, Cell Therapy Search and Evaluation, Kite Pharma / Gilead Sciences

Moderator:

Michael Kalos, PhD, Managing Director, Next Pillar Consulting

1:55PM - 2:15PM

Development Progress and Opportunities for CAR-T in Autoimmune Disease

Speaker:

Gwendolyn Binder, PhD, President, Science & Technology, Cabaletta Bio

2:15PM - 2:35PM

Innovations in Manufacturing and Potency Enhancement for Enhanced Accessibility and Affordability

Speaker:

Greg Sawyer, PhD, Chief BioEngineering Officer, Chair, Department of BioEngineering, Moffitt Cancer Center

2:35PM - 3:20PM

Panel: Addressing the Realities of Scalability in T-Cell Therapies - Achieving Accessible and Affordable Treatment for All

Moderator:

Greg Sawyer, PhD, Chief BioEngineering Officer, Chair, Department of BioEngineering, Moffitt Cancer Center

Panelists:

Serena De Vita, MD, PhD, VP, Global Franchise Head and Global Clinical Strategy Head, Late Development Oncology, Cell Therapy, AstraZeneca

Arvind Natarajan, PhD, MBA, SVP, Process and Analytical Development, Iovance Biotherapeutics Inc

Sarah Warren, PhD, Senior Director, Corporate Development Lead, Cell Therapy Search and Evaluation, Kite Pharma / Gilead Sciences

Showing Events in 1 Track from 03:20pm to 04:00pm

IO360° Afternoon Networking Break, 1:1 Partnering Meetings & Poster Sessions

3:20PM - 4:00PM

IO360° Afternoon Networking Break, 1:1 Partnering Meetings & Poster Sessions

3:25PM - 3:55PM

IO360° Poster Sessions

Poster Presenters:

David A. Braun, MD, PhD, Louis Goodman and Alfred Gilman Yale Scholar & Assistant Professor of Medicine, Pathology, and Urology, Yale School of Medicine

Jay Fine, PhD, President, Research & Development, EvolveImmune Therapeutics

Chiquita Hanindya, Scientist, Cell Biology, BlueWhale Bio

Gopal Krishnan, PhD, Manager, Biologics, Promega

Ramji Srinivasan, Co-founder and CEO, Teiko.bio

Kristen Wangerin, PhD, Senior Imaging Technology Leader, Pharmaceutical Diagnostics, GE HealthCare

Alia Zander, PhD, Senior Data Scientist, Machine Learning, Tempus

Jenny Zilberberg, PhD, Head of Research, Imvax, Inc.

Showing Events in 4 Tracks from 04:00pm to 05:25pm

Track 2: Breakthroughs in Translational Science, Imaging and Biomarkers 2
Back Bay Ballroom AB

Track Chair:

Hanif Gabrani-Juma, BEng, MASc, Associate Director – Translational Medicine Strategy Radiology Imaging & AI, Oncology R&D Cancer Biomarker Development, AstraZeneca

4:00PM - 4:20PM

Active Immunotherapy to Achieve Durable Remissions in MRD + AML

Speaker:

Erik Manting, PhD, CEO, Mendus

4:20PM - 4:35PM

Progress on Multiplexed IHC CDx: Advancing Spatial Biology for Clinical Impact

Speaker:

Mark Landers, VP of Precision Medicine, Akoya Biosciences Inc.

4:35PM - 4:55PM

Picking our Horse in the Race for Auto-immunity: The Gamma-Delta T-cell Engager

Speaker:

William Ho, MBA, President & CEO, IN8Bio

4:55PM - 5:10PM

Leveraging the Predictive Power of Liquid Biopsy for IO Treatment Response Monitoring

Speaker:

Kristin Price, Senior Product Director, Guardant Health

5:10PM - 5:25PM

Targeting Metastatic Cancer and Immune Resistance Using Nucleic Acid Therapies

Speaker:

Zdravka Medarova, PhD, CSO & Co-founder, TransCode Therapeutics

Track 3: Cell Therapy - Innovations in Process to Generate Cell Therapies
Constitution Ballroom A

Track Chair:

Rosanna Ricafort, MD, VP and Head, Hematology and Cellular Therapy Development, BMS

4:00PM - 4:15PM

Accelerating Cell Therapy: Innovations in Streamlining the Cell Manufacturing Process

Speaker:

Saba Ghassemi, PhD, Research Assistant; Professor of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania

4:15PM - 4:30PM

Non-Viral Vectors Delivering Stably Integrating DNA for In Vivo CAR T Therapy

Speaker:

Maurits Geerlings, MD, MBA, President & CEO, NanoCell Therapeutics, Inc

4:30PM - 4:45PM

In Vivo CD19 and CD22 CAR-T Cell Therapeutics for B Cell Malignancies

Speaker:

Andrew Scharenberg, MD, Co-Founder & CEO, Umoja Biopharma

4:45PM - 5:00PM

Implantable Biofactories for Bedside CAR T Cell Therapy

Speaker:

Yevgeny Brudno, PhD, Associate Professor, University of North Carolina at Chapel Hill and North Carolina State University

5:00PM - 5:15PM

Multiplexed CRISPR Cas9 Editing to Generate Next-Generation Allogeneic CAR-T Cells

Speaker:

Birgit Schultes, PhD, SVP, Head of Cell Therapies, Intellia Therapeutics

Track 4: Cell Therapy - Innovations in Cell Types Employed in Cell Therapies
Constitution Ballroom B

Track Chair:

Michael Kalos, PhD, Managing Director, Next Pillar Consulting

4:00PM - 4:15PM

Going with the Flow: Circulating Tumor Reactive Lymphocytes (cTRL) Stream into Cancer Therapy

Speaker:

Ruben Rodriguez, PhD, Head of Research, cTRL Therapeutics

4:15PM - 4:30PM

B Cell Medicines – A New Class of In Vivo Biologics

Speaker:

Joanne Smith-Farrell, PhD, CEO & Director, Be Bio

4:30PM - 4:45PM

Programming T Cells with Synthetic Immunology to Overcome Solid Tumor Barriers

Speaker:

Aaron Cooper, PhD, VP, Early Discovery, ArsenalBio

Track 1: Breakthroughs in Translational Science, Imaging and Biomarkers 1
Grand Ballroom

Track Chair:

Samik Upadhaya, PhD, Director of Scientific Affairs, Cancer Research Institute (CRI)

4:00PM - 4:20PM

Innovative Non-Cell CAR-T Strategies: Harnessing Bispecifics and Co-Stimulators for Enhanced Immunotherapy

Speaker:

Ashley Lakner, PhD, Head, Oncology Discovery - pRED Oncology, Roche

4:20PM - 4:35PM

Whole-body Visualization of Immune Cell Infiltration in Solid Tumors Using 18F CD8 PET/CT Imaging

Speaker:

Kristen Wangerin, PhD, Senior Imaging Technology Leader, Pharmaceutical Diagnostics, GE HealthCare

4:35PM - 4:55PM

Advancements in Tumor Targeting: Clinical and Preclinical Insights from DK210 (EGFR)

Speaker:

John Mumm, PhD, President & CEO, DEKA Biosciences

4:55PM - 5:10PM

Advancing Drug Development Through Deep Learning Analysis of H&E and IHC Pathology Images

Speaker:

Siraj Ali, MD, PhD, Global VP of Translational Medicine, Lunit

Track 2: Breakthroughs in Translational Science, Imaging and Biomarkers 2
Back Bay Ballroom AB

Track Chair:

Hanif Gabrani-Juma, BEng, MASc, Associate Director – Translational Medicine Strategy Radiology Imaging & AI, Oncology R&D Cancer Biomarker Development, AstraZeneca

4:00PM - 4:20PM

Active Immunotherapy to Achieve Durable Remissions in MRD + AML

Speaker:

Erik Manting, PhD, CEO, Mendus

4:20PM - 4:35PM

Progress on Multiplexed IHC CDx: Advancing Spatial Biology for Clinical Impact

Speaker:

Mark Landers, VP of Precision Medicine, Akoya Biosciences Inc.

4:35PM - 4:55PM

Picking our Horse in the Race for Auto-immunity: The Gamma-Delta T-cell Engager

Speaker:

William Ho, MBA, President & CEO, IN8Bio

4:55PM - 5:10PM

Leveraging the Predictive Power of Liquid Biopsy for IO Treatment Response Monitoring

Speaker:

Kristin Price, Senior Product Director, Guardant Health

5:10PM - 5:25PM

Targeting Metastatic Cancer and Immune Resistance Using Nucleic Acid Therapies

Speaker:

Zdravka Medarova, PhD, CSO & Co-founder, TransCode Therapeutics

Track 3: Cell Therapy - Innovations in Process to Generate Cell Therapies
Constitution Ballroom A

Track Chair:

Rosanna Ricafort, MD, VP and Head, Hematology and Cellular Therapy Development, BMS

4:00PM - 4:15PM

Accelerating Cell Therapy: Innovations in Streamlining the Cell Manufacturing Process

Speaker:

Saba Ghassemi, PhD, Research Assistant; Professor of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania

4:15PM - 4:30PM

Non-Viral Vectors Delivering Stably Integrating DNA for In Vivo CAR T Therapy

Speaker:

Maurits Geerlings, MD, MBA, President & CEO, NanoCell Therapeutics, Inc

4:30PM - 4:45PM

In Vivo CD19 and CD22 CAR-T Cell Therapeutics for B Cell Malignancies

Speaker:

Andrew Scharenberg, MD, Co-Founder & CEO, Umoja Biopharma

4:45PM - 5:00PM

Implantable Biofactories for Bedside CAR T Cell Therapy

Speaker:

Yevgeny Brudno, PhD, Associate Professor, University of North Carolina at Chapel Hill and North Carolina State University

5:00PM - 5:15PM

Multiplexed CRISPR Cas9 Editing to Generate Next-Generation Allogeneic CAR-T Cells

Speaker:

Birgit Schultes, PhD, SVP, Head of Cell Therapies, Intellia Therapeutics

Track 4: Cell Therapy - Innovations in Cell Types Employed in Cell Therapies
Constitution Ballroom B

Track Chair:

Michael Kalos, PhD, Managing Director, Next Pillar Consulting

4:00PM - 4:15PM

Going with the Flow: Circulating Tumor Reactive Lymphocytes (cTRL) Stream into Cancer Therapy

Speaker:

Ruben Rodriguez, PhD, Head of Research, cTRL Therapeutics

4:15PM - 4:30PM

B Cell Medicines – A New Class of In Vivo Biologics

Speaker:

Joanne Smith-Farrell, PhD, CEO & Director, Be Bio

4:30PM - 4:45PM

Programming T Cells with Synthetic Immunology to Overcome Solid Tumor Barriers

Speaker:

Aaron Cooper, PhD, VP, Early Discovery, ArsenalBio

Track 1: Breakthroughs in Translational Science, Imaging and Biomarkers 1
Grand Ballroom

Track Chair:

Samik Upadhaya, PhD, Director of Scientific Affairs, Cancer Research Institute (CRI)

4:00PM - 4:20PM

Innovative Non-Cell CAR-T Strategies: Harnessing Bispecifics and Co-Stimulators for Enhanced Immunotherapy

Speaker:

Ashley Lakner, PhD, Head, Oncology Discovery - pRED Oncology, Roche

4:20PM - 4:35PM

Whole-body Visualization of Immune Cell Infiltration in Solid Tumors Using 18F CD8 PET/CT Imaging

Speaker:

Kristen Wangerin, PhD, Senior Imaging Technology Leader, Pharmaceutical Diagnostics, GE HealthCare

4:35PM - 4:55PM

Advancements in Tumor Targeting: Clinical and Preclinical Insights from DK210 (EGFR)

Speaker:

John Mumm, PhD, President & CEO, DEKA Biosciences

4:55PM - 5:10PM

Advancing Drug Development Through Deep Learning Analysis of H&E and IHC Pathology Images

Speaker:

Siraj Ali, MD, PhD, Global VP of Translational Medicine, Lunit

Track 2: Breakthroughs in Translational Science, Imaging and Biomarkers 2
Back Bay Ballroom AB

Track Chair:

Hanif Gabrani-Juma, BEng, MASc, Associate Director – Translational Medicine Strategy Radiology Imaging & AI, Oncology R&D Cancer Biomarker Development, AstraZeneca

4:00PM - 4:20PM

Active Immunotherapy to Achieve Durable Remissions in MRD + AML

Speaker:

Erik Manting, PhD, CEO, Mendus

4:20PM - 4:35PM

Progress on Multiplexed IHC CDx: Advancing Spatial Biology for Clinical Impact

Speaker:

Mark Landers, VP of Precision Medicine, Akoya Biosciences Inc.

4:35PM - 4:55PM

Picking our Horse in the Race for Auto-immunity: The Gamma-Delta T-cell Engager

Speaker:

William Ho, MBA, President & CEO, IN8Bio